1-11 of 11
Peter D. Senter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47

Matthew R. Levengood, Christopher M. Carosino, Xinqun Zhang, Sasha Lucas, David J. Ortiz, Lori Westendorf, Alice P. Chin, Arlan D. Martin, Abbie Wong, Shawna M. Hengel, Hao Sun, Weiping Zeng, Roma Yumul, Melissa M.C. Dominguez, Yufei Chen, Janet H. Zheng, Courtney A.B. Karlsson, Vivian H. Trang, Peter D. Senter, Shyra J. Gardai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF14.
https://doi.org/10.1158/1535-7163.MCT-24-0371
Published: 22 November 2024
View article titled, Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Open the PDF for Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47 in another window
Includes: Supplementary data
Journal Articles

Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models

Philip N. Moquist, Tim D. Bovee, Andrew B. Waight, Jamie A. Mitchell, Jamie B. Miyamoto, Marsha L. Mason, Kim K. Emmerton, Nicole Stevens, Cindy Balasubramanian, Jessica K. Simmons, Robert P. Lyon, Peter D. Senter, Svetlana O. Doronina
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (2): 320–328.
https://doi.org/10.1158/1535-7163.MCT-20-0618
Published: 05 February 2021
View article titled, Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models
Open the PDF for Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models in another window
Includes: Supplementary data
Journal Articles

Development of Novel Antibody–Camptothecin Conjugates

Ryan D. Lyski, Lauren B. Bou, Uland Y. Lau, David W. Meyer, Julia H. Cochran, Nicole M. Okeley, Kim K. Emmerton, Francisco Zapata, Jessica K. Simmons, Esther S. Trueblood, David J. Ortiz, Margo C. Zaval, Katie M. Snead, Steven Jin, Lauren M. Farr, Maureen C. Ryan, Peter D. Senter, Scott C. Jeffrey
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (2): 329–339.
https://doi.org/10.1158/1535-7163.MCT-20-0526
Published: 05 February 2021
View article titled, Development of Novel Antibody–Camptothecin Conjugates
Open the PDF for Development of Novel Antibody–Camptothecin Conjugates in another window
Includes: Supplementary data
Journal Articles

Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers

Mary L. Disis, Lauren R. Corulli, Ekram A. Gad, Marlese R. Koehnlein, Denise L. Cecil, Peter D. Senter, Shyra J. Gardai, Nicole M. Okeley
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (5): 1102–1109.
https://doi.org/10.1158/1535-7163.MCT-19-0500
Published: 04 May 2020
View article titled, Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers
Open the PDF for Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract A097: Tubulysin ADC payloads: An antimitotic drug class that retains activity in multidrug resistant models

Patrick J Burke, Joseph Z Hamilton, Thomas A Pires, Kim K Emmerton, Peter D Senter, Scott C Jeffrey
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A097.
https://doi.org/10.1158/1535-7163.TARG-19-A097
Published: 01 December 2019
View article titled, Abstract A097: Tubulysin ADC payloads: An antimitotic drug class that retains activity in multidrug resistant models
Journal Articles

Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates

Christopher S. Neumann, Kathleen C. Olivas, Martha E. Anderson, Julia H. Cochran, Steven Jin, Fu Li, Luke V. Loftus, David W. Meyer, Jason Neale, Jay C. Nix, Paul G. Pittman, Jessica K. Simmons, Michelle L. Ulrich, Andrew B. Waight, Abbie Wong, Margo C. Zaval, Weiping Zeng, Robert P. Lyon, Peter D. Senter
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (12): 2633–2642.
https://doi.org/10.1158/1535-7163.MCT-18-0643
Published: 03 December 2018
View article titled, Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates
Open the PDF for Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates in another window
Includes: Supplementary data
Journal Articles

Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models

Patrick J. Burke, Joseph Z. Hamilton, Thomas A. Pires, Holden W.H. Lai, Christopher I. Leiske, Kim K. Emmerton, Andrew B. Waight, Peter D. Senter, Robert P. Lyon, Scott C. Jeffrey
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (8): 1752–1760.
https://doi.org/10.1158/1535-7163.MCT-18-0073
Published: 31 July 2018
View article titled, Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR<sup>+</sup> and Heterogeneous Tumor Models
Open the PDF for Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR<sup>+</sup> and Heterogeneous Tumor Models in another window
Includes: Supplementary data
Journal Articles

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

Fu Li, May Kung Sutherland, Changpu Yu, Roland B. Walter, Lori Westendorf, John Valliere-Douglass, Lucy Pan, Ashley Cronkite, Django Sussman, Kerry Klussman, Michelle Ulrich, Martha E. Anderson, Ivan J. Stone, Weiping Zeng, Mechthild Jonas, Timothy S. Lewis, Maitrayee Goswami, Sa A. Wang, Peter D. Senter, Che-Leung Law, Eric J. Feldman, Dennis R. Benjamin
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (2): 554–564.
https://doi.org/10.1158/1535-7163.MCT-17-0742
Published: 01 February 2018
View article titled, Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
Open the PDF for Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates

Patrick J. Burke, Joseph Z. Hamilton, Scott C. Jeffrey, Joshua H. Hunter, Svetlana O. Doronina, Nicole M. Okeley, Jamie B. Miyamoto, Martha E. Anderson, Ivan J. Stone, Michelle L. Ulrich, Jessica K. Simmons, Erica E. McKinney, Peter D. Senter, Robert P. Lyon
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (1): 116–123.
https://doi.org/10.1158/1535-7163.MCT-16-0343
Published: 05 January 2017
View article titled, Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates
Open the PDF for Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates in another window
Includes: Supplementary data
Journal Articles

Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates

Patrick J. Burke, Joseph Z. Hamilton, Thomas A. Pires, Jocelyn R. Setter, Joshua H. Hunter, Julia H. Cochran, Andrew B. Waight, Kristine A. Gordon, Brian E. Toki, Kim K. Emmerton, Weiping Zeng, Ivan J. Stone, Peter D. Senter, Robert P. Lyon, Scott C. Jeffrey
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (5): 938–945.
https://doi.org/10.1158/1535-7163.MCT-16-0038
Published: 05 May 2016
View article titled, Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates
Open the PDF for Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates in another window
Includes: Supplementary data
Journal Articles

Abstract B133: SEA technology: A novel strategy for enhancing antibody effector function

Stephen C. Alley, Django R. Sussman, Scott C. Jeffrey, Lindsay Torrey, Patrick J. Burke, Kerry Klussman, Nicole M. Okeley, Peter D. Senter, Dennis R. Benjamin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B133.
https://doi.org/10.1158/1535-7163.TARG-09-B133
Published: 10 December 2009
View article titled, Abstract B133: SEA technology: A novel strategy for enhancing antibody effector function